SUPERNUS PHARMACEUTICALS INC (SUPN)
Sector: Health Care
2026 Annual Meeting Analysis
SUPERNUS PHARMACEUTICALS INC · Meeting: June 18, 2026
Directors FOR
2
Directors AGAINST
0
Say on Pay
AGAINST
Auditor
FOR
Director Elections
Election of Two Class II Directors to Hold Office for Three Years
Hudson has served since 2010 with strong relevant qualifications as a retired KPMG partner and healthcare audit specialist; SUPN's 3-year stock return of +30.6% outperforms the disclosed peer group median by +6.1 percentage points, well below the 65pp threshold required to trigger a vote against at this positive return level, and no overboarding, attendance, or independence concerns are present.
Newhall has served as Chairman since 2016 and brings extensive venture capital and healthcare board experience; the same peer-group TSR analysis applies — SUPN outperforms peers by +6.1pp over three years, far short of the 65pp underperformance threshold needed to trigger a vote against, and no overboarding, attendance, or independence issues are identified.
Both Class II nominees pass all policy screens: no TSR underperformance trigger fires (SUPN's 3-year return of +30.6% beats the peer median by +6.1pp, versus a 65pp trigger threshold), no overboarding, full meeting attendance reported, and both directors have strong relevant qualifications for a specialty pharmaceutical company.
Say on Pay
✗ AGAINSTCEO
Jack A. Khattar
Total Comp
$15,501,557
Prior Support
96%%
The CEO received total compensation of approximately $15.5 million for 2025, which is very high for a specialty pharmaceutical company with a $2.8 billion market cap — our independent benchmark for a CEO at this company size and sector suggests total pay should be materially lower, and the CEO's package exceeds the +20% individual threshold that triggers a No vote. While the company's stock has performed reasonably well and the prior Say on Pay vote showed 96% support, the compensation structure raises concerns: the performance stock awards vest on individual operational milestones rather than market-based or long-term financial return targets, which means a large portion of what is labeled 'performance pay' functions more like guaranteed equity; additionally, the CEO's daughter was employed by the company in a management role through the end of 2025, which is a related-party relationship that warrants scrutiny of whether the compensation committee exercises fully independent judgment over CEO pay. On balance, the pay level concern for the CEO is the primary trigger for the Against vote.
Auditor Ratification
✓ FORAuditor
KPMG LLP
Tenure
N/A
Audit Fees
N/A
Non-Audit Fees
N/A
The proxy filing does not include an auditor fee table with specific dollar amounts, so the non-audit fee ratio trigger cannot be evaluated — under policy, when tenure is not disclosed or cannot be confirmed, the tenure trigger does not fire. KPMG is a Big 4 firm appropriate for a $2.8B market cap company, no material restatements are disclosed, and no other disqualifying conditions are identified, so the default vote applies.
Overall Assessment
The 2026 Supernus annual meeting presents four proposals: both Class II director nominees pass all policy screens and receive FOR votes given solid stock performance versus peers and strong qualifications; the auditor ratification receives a FOR vote as KPMG is appropriate for the company's size and no fee or restatement concerns are identified; Say on Pay receives an AGAINST vote driven primarily by CEO total compensation of $15.5 million that appears materially above the independent benchmark for a $2.8B specialty pharma company, compounded by performance awards tied to individual operational milestones rather than rigorous long-term financial metrics. The equity plan share increase (Proposal 4) falls outside current policy coverage and is not evaluated.
Compensation Peer Group
16 companies disclosed in 2026 proxy filing